Comparison · NCT04194944-sae
Selpercatinib (TRT A) vs Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Selpercatinib (TRT A) vs Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B): serious adverse events. Trial comparisons, record NCT04194944-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04194944-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.348 | 0.278 | 0.425 | wilson | |
| Risk in group 2 | 0.235 | 0.162 | 0.328 | wilson | |
| Risk difference, group 1 minus group 2 | 0.113 | -0.00286 | 0.22 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.48 | 0.978 | 2.25 | log | |
| Odds ratio, group 1 over group 2 | 1.74 | 0.984 | 3.08 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Selpercatinib (TRT A) than on Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 8.82 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Selpercatinib (TRT A) | 160 milligram (mg) Selpercatinib administered orally, twice daily (BID continuously in 21-day cycles. | 55 | 158 | EG000 |
| Group 2 | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus at the investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \[maximum dose 750 mg\]) IV, or cisplatin 75mg/m2 IV on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles. | 23 | 98 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline Up to 38 Months
Source ClinicalTrials.gov
Trial
- Title
- A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- NCT number
- NCT04194944
- Phases
- PHASE3
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2024-06-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04194944?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04194944-sae